Einloggen

Thematische Bibliographien / Dopamine type I receptor / Bücher

Bücher zum Thema „Dopamine type I receptor“

Um die anderen Arten von Veröffentlichungen zu diesem Thema anzuzeigen, folgen Sie diesem Link: Dopamine type I receptor.

Autor: Grafiati

Veröffentlicht am 19. Oktober 2024

Geben Sie eine Quelle nach APA, MLA, Chicago, Harvard und anderen Zitierweisen an

Wählen Sie eine Art der Quelle aus:

Machen Sie sich mit Top-50 Bücher für die Forschung zum Thema "Dopamine type I receptor" bekannt.

Neben jedem Werk im Literaturverzeichnis ist die Option "Zur Bibliographie hinzufügen" verfügbar. Nutzen Sie sie, wird Ihre bibliographische Angabe des gewählten Werkes nach der nötigen Zitierweise (APA, MLA, Harvard, Chicago, Vancouver usw.) automatisch gestaltet.

Sie können auch den vollen Text der wissenschaftlichen Publikation im PDF-Format herunterladen und eine Online-Annotation der Arbeit lesen, wenn die relevanten Parameter in den Metadaten verfügbar sind.

Sehen Sie die Bücher für verschiedene Spezialgebieten durch und erstellen Sie Ihre Bibliographie auf korrekte Weise.

1

Tupala, Erkki. Dopamine receptors and transporters in type 1 and 2 alcoholism measured with postmortem human whole hemisphere autoradiography. Kuopio: University of Kuopio, 2001.

Den vollen Inhalt der Quelle finden

APA, Harvard, Vancouver, ISO und andere Zitierweisen

2

Tiberi, Mario. Dopamine receptor technologies. New York, NY: Humana Press, 2015.

Den vollen Inhalt der Quelle finden

APA, Harvard, Vancouver, ISO und andere Zitierweisen

3

Tiberi, Mario, Hrsg. Dopamine Receptor Technologies. New York, NY: Springer New York, 2015. http://dx.doi.org/10.1007/978-1-4939-2196-6.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

4

Donthamsetti, Prashant Chandra. Dissecting Dopamine D2 Receptor Signaling. [New York, N.Y.?]: [publisher not identified], 2015.

Den vollen Inhalt der Quelle finden

APA, Harvard, Vancouver, ISO und andere Zitierweisen

5

L, Waddington John, Hrsg. D1:D2 dopamine receptor interactions. London: Academic Press, 1993.

Den vollen Inhalt der Quelle finden

APA, Harvard, Vancouver, ISO und andere Zitierweisen

6

Boileau, Isabelle, und Ginetta Collo, Hrsg. Therapeutic Applications of Dopamine D3 Receptor Function. Cham: Springer International Publishing, 2023. http://dx.doi.org/10.1007/978-3-031-23058-5.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

7

Knapp, Mark. Development of dopamine receptor expressing adenoviral vectors. Ottawa: National Library of Canada, 1997.

Den vollen Inhalt der Quelle finden

APA, Harvard, Vancouver, ISO und andere Zitierweisen

8

R, Demirdamar, und Jenner Peter 1946-, Hrsg. Dopamine receptor subtypes: From basic science to clinical application. Amsterdam: IOS Press, 1998.

Den vollen Inhalt der Quelle finden

APA, Harvard, Vancouver, ISO und andere Zitierweisen

9

Ray, Avi Andrew. SH3 binding domains in the dopamine D(3) receptor. Ottawa: National Library of Canada, 1999.

Den vollen Inhalt der Quelle finden

APA, Harvard, Vancouver, ISO und andere Zitierweisen

10

Zawarynski, Paul. Dopamine D2 receptor monomers, dimers and higher order oligomers. Ottawa: National Library of Canada, 1998.

Den vollen Inhalt der Quelle finden

APA, Harvard, Vancouver, ISO und andere Zitierweisen

11

O'Connor, Noreen A. D and D dopamine receptor signal transduction in transfected cell lines. Dublin: University College Dublin, 1998.

Den vollen Inhalt der Quelle finden

APA, Harvard, Vancouver, ISO und andere Zitierweisen

12

Costanza, Rino Michelangelo. Dopamine receptor subtype involvement in the behavioural effects of cocaine. Birmingham: University of Birmingham, 1999.

Den vollen Inhalt der Quelle finden

APA, Harvard, Vancouver, ISO und andere Zitierweisen

13

Lappalainen, Jaakko. Neurochemical and behavioural effects of dopamine D[sub]1 receptor blockade. Turku: J. Lappalainen, 1992.

Den vollen Inhalt der Quelle finden

APA, Harvard, Vancouver, ISO und andere Zitierweisen

14

Malmberg, Åsa. Dopamine D2 and D3 receptor-ligand interactions: Molecular pharmacology and medicinal chemistry. Uppsala: Acta Universitatis Upsaliensis, 1996.

Den vollen Inhalt der Quelle finden

APA, Harvard, Vancouver, ISO und andere Zitierweisen

15

Asghari, Vida. Structural, pharmacological, and functional characterization of polymorphic human dopamine D4 receptor isoforms. Ottawa: National Library of Canada, 1994.

Den vollen Inhalt der Quelle finden

APA, Harvard, Vancouver, ISO und andere Zitierweisen

16

Sanyal, Suparna. Pharmacological and functional characterization of the polymorphic human dopamine D4 receptor isoforms. Ottawa: National Library of Canada, 1996.

Den vollen Inhalt der Quelle finden

APA, Harvard, Vancouver, ISO und andere Zitierweisen

17

Hamadanizadeh, Soheila A. Pharmacological and functional differentiation of dopamine D1c and D1d receptor subtypes: Two novel members of the D1-like receptor family. Ottawa: National Library of Canada, 1996.

Den vollen Inhalt der Quelle finden

APA, Harvard, Vancouver, ISO und andere Zitierweisen

18

elmhurst, Jennifer Lynne. characterization of the D3 dopamine receptor and a splice variant, D3NF, in SF9 cells. Ottawa: National Library of Canada, 1998.

Den vollen Inhalt der Quelle finden

APA, Harvard, Vancouver, ISO und andere Zitierweisen

19

Tsatsos, Jim. Nicotine regulates opioid peptide and dopamine receptor gene expression in the rat brain and pituitary. Ottawa: National Library of Canada = Bibliothèque nationale du Canada, 1993.

Den vollen Inhalt der Quelle finden

APA, Harvard, Vancouver, ISO und andere Zitierweisen

20

Yano, Hideaki. Deconstructing G Protein-Coupled Receptor Dimer Pharmacology: Case Studies in Dopamine D1 and D2 Receptors. [New York, N.Y.?]: [publisher not identified], 2012.

Den vollen Inhalt der Quelle finden

APA, Harvard, Vancouver, ISO und andere Zitierweisen

21

Rusk, Ilene Naomi. The effects of selective dopamine D [inferior] 1 and D [inferior] 2 agonists and antagonists on feeding and associated behaviour. Birmingham: University of Birmingham, 1989.

Den vollen Inhalt der Quelle finden

APA, Harvard, Vancouver, ISO und andere Zitierweisen

22

Mukherjee, Tinku S. Regulation of the D1 dopamine receptor in rat brain and SK-N-Mc human neuroblastoma cells. Ottawa: National Library of Canada = Bibliothèque nationale du Canada, 1995.

Den vollen Inhalt der Quelle finden

APA, Harvard, Vancouver, ISO und andere Zitierweisen

23

Johnson, T. The preparation of some novel 2-[2-arylethyl]catecholamines required for evaluation as peripheral dopamine receptor agonists. Norwich: University of East Anglia, 1994.

Den vollen Inhalt der Quelle finden

APA, Harvard, Vancouver, ISO und andere Zitierweisen

24

Lamey, Michael. Identification of distinct residues in the carboxyl tail regulating desensitization and internalization of the D1 dopamine receptor. Ottawa: National Library of Canada, 2000.

Den vollen Inhalt der Quelle finden

APA, Harvard, Vancouver, ISO und andere Zitierweisen

25

Timothy V. P. C. Beischlag. Molecular cloning and characterization of the 5'-flanking and promoter region of the human dopamine D5 receptor gene. Ottawa: National Library of Canada = Bibliothèque nationale du Canada, 1996.

Den vollen Inhalt der Quelle finden

APA, Harvard, Vancouver, ISO und andere Zitierweisen

26

Sanci, Vito. Effect of chronic haloperidol, endogenous dopamine, and selective D1 competitors on in vivo D1 receptor binding in rat brain. Ottawa: National Library of Canada, 2000.

Den vollen Inhalt der Quelle finden

APA, Harvard, Vancouver, ISO und andere Zitierweisen

27

Ko, Francoise Dulcinea. Effect of GABARAP (GABA(A)-receptor-associated protein on the interaction between the dopamine D(5) and GABA(A) receptors. Ottawa: National Library of Canada, 2001.

Den vollen Inhalt der Quelle finden

APA, Harvard, Vancouver, ISO und andere Zitierweisen

28

Wigmore, Mark Aubrey. Depression of glutamate input and excitation of midbrain dopamine neurones by metabotropic glutamate receptor activation: An electrophysiological study in rat brain slices. Birmingham: University of Birmingham, 1997.

Den vollen Inhalt der Quelle finden

APA, Harvard, Vancouver, ISO und andere Zitierweisen

29

Playford, Martin P. The role of the type 1 insulin-like growth factor receptor in cancer biology. Oxford: Oxford Brookes University, 2000.

Den vollen Inhalt der Quelle finden

APA, Harvard, Vancouver, ISO und andere Zitierweisen

30

Johansson, P. J. Hugo. Herpes simplex virus type 1 induced IgG Fc receptor: Aspects of specificity and function. Lund: Univ., 1989.

Den vollen Inhalt der Quelle finden

APA, Harvard, Vancouver, ISO und andere Zitierweisen

31

Cheung, Hermia. Effect of dopamine depletion on D1 receptor binding in rat brain; and metabolism studies of D1 agonist R-[11C]SKF 82957 and phosphodiesterase-4 inhibitor R-[11C}rolipram. Ottawa: National Library of Canada, 2003.

Den vollen Inhalt der Quelle finden

APA, Harvard, Vancouver, ISO und andere Zitierweisen

32

1929-, Shigeta Yukio, Kobayashi Masashi Dr und Olefsky Jerrold M, Hrsg. Recent advances in insulin action and its disorders: Proceedings of the International Symposium on Insulin Action and Its Disorders, Shiga, 16 May 1990. Amsterdam: Excerpta Medica, 1991.

Den vollen Inhalt der Quelle finden

APA, Harvard, Vancouver, ISO und andere Zitierweisen

33

Flavin, Nora. Cloning and characterisation of the bovine activin receptor type II gene (ActRII): Its localisation to chromosome 2 (BTA2) by somatic cell genetic analysis and the genotyping of an associated microsatelltie UCD2. Dublin: University College Dublin, 1996.

Den vollen Inhalt der Quelle finden

APA, Harvard, Vancouver, ISO und andere Zitierweisen

34

(Editor), Peter Jenner, und R. Demirdamar (Editor), Hrsg. Dopamine Receptor Sub-Types: From Basic Sciences to Clinical Applications (Biomedical and Health Research, Vol. 19) (Biomedical and Health Research, V. 19). Ios Pr Inc, 1997.

Den vollen Inhalt der Quelle finden

APA, Harvard, Vancouver, ISO und andere Zitierweisen

35

Nielsen, David A., Dmitri Proudnikov und Mary Jeanne Kreek. The Genetics of Impulsivity. Herausgegeben von Jon E. Grant und Marc N. Potenza. Oxford University Press, 2012. http://dx.doi.org/10.1093/oxfordhb/9780195389715.013.0080.

Der volle Inhalt der Quelle

Annotation:

Impulsivity is a complex trait that varies across healthy individuals, although when excessive, it is generally regarded as dysfunctional. Impulsive behavior may lead to initiation of drug addiction that interferes with inhibitory controls, which may in turn result in facilitation of the individual’s impulsive acts. Although environmental factors play a considerable role in impulsive behavior, a body of evidence collected in twin studies suggests that about 45% of the variance in impulsivity is accounted for by genetic factors. Genetic variants studied in association with impulsivity include those fortryptophan hydroxylase 1 and 2 (TPH1 and TPH2), the serotonintransporter (SERT), serotonin receptors, and genes of the monoamine metabolism pathway (e.g., monoamine oxidase A, MAOA). Other systems may also play a role in these behaviors, such as the dopaminergic system (the dopamine receptors DRD2, DRD3, and DRD4, and the dopamine transporter, DAT), the catecholaminergic system (catechol-O-methyltransferase, COMT), and the GABAergic system (GABAreceptor subunit alpha-1, GABRA1; GABA receptor subunit alpha-6, GABRA6; and GABA receptor subunit beta-1, GABRB1). Taking into account involvement of the hypothalamic-pituitary-adrenal (HPA) axis, the number of candidate genes implicated in impulsivity may be increased significantly and, therefore, may go far beyond those of serotonergic and dopaminergic systems. For a number of years, our group has conducted studies of the association of genes involved in the modulation of the stress-responsive HPA axis and several neurotransmitter systems, all involved in the pathophysiology of anxiety and depressive disorders, impulse control and compulsive disorders, with drug addiction. These genes include those of the opioid system: the mu- and kappa-opioid receptors (OPRM1 and OPRK1) and the nociceptin/orphaninFQ receptor (OPRL1); the serotonergic system: TPH1 and TPH2 and the serotonin receptor 1B (5THR1B); the catecholamine system: COMT; the HPA axis: themelanocortin receptor type 2 (MC2R or adrenocorticotropic hormone, ACTHR); and the cannabinoid system: the cannabinoid receptor type 1 (CNR1). In this chapter we will focus on these findings.

APA, Harvard, Vancouver, ISO und andere Zitierweisen

36

Poste, George, und Stanley T. Crooke. Dopamine Receptor Agonists. Springer, 2013.

Den vollen Inhalt der Quelle finden

APA, Harvard, Vancouver, ISO und andere Zitierweisen

37

Poste, George, und Stanley T. Crooke. Dopamine Receptor Agonists. Springer, 2012.

Den vollen Inhalt der Quelle finden

APA, Harvard, Vancouver, ISO und andere Zitierweisen

38

Tiberi, Mario. Dopamine Receptor Technologies. Humana Press, 2016.

Den vollen Inhalt der Quelle finden

APA, Harvard, Vancouver, ISO und andere Zitierweisen

39

Poste, George, und Stanley T. Crooke. Dopamine Receptor Agonists. Springer, 2013.

Den vollen Inhalt der Quelle finden

APA, Harvard, Vancouver, ISO und andere Zitierweisen

40

Fox, Susan H. Delayed and Often Persistent. Oxford University Press, 2016. http://dx.doi.org/10.1093/med/9780190607555.003.0021.

Der volle Inhalt der Quelle

Annotation:

Tardive syndromes are drug-induced hyperkinetic movement disorders that occur as a consequence of dopamine D2 receptor antagonism/blockade. There are several types, including classical tardive dyskinesia, tardive dystonia, tardive tics, tardive myoclonus, and tardive tremor, and it is important to the management of these disorders that the type of movement disorder induced is identified. Tardive syndromes can occur with all antipsychotic drugs, including so-called atypical drugs. Patients taking these drugs should be evaluated frequently for side effects. Evaluating the nature of the movement (i.e., chorea or dystonia) is important because treatment options can differ according to the type of dyskinesia present.

APA, Harvard, Vancouver, ISO und andere Zitierweisen

41

Otsuka, Norman Yoshinobu. Dopamine D r receptor solubilization. 1985.

Den vollen Inhalt der Quelle finden

APA, Harvard, Vancouver, ISO und andere Zitierweisen

42

Sugamori, Kim S. The dopamine D1C receptor expansion and origin of the dopamine D1 receptor family. 1999.

Den vollen Inhalt der Quelle finden

APA, Harvard, Vancouver, ISO und andere Zitierweisen

43

Beninger, Richard J. Dopamine receptor subtypes and incentive learning. Oxford University Press, 2018. http://dx.doi.org/10.1093/oso/9780198824091.003.0007.

Der volle Inhalt der Quelle

Annotation:

Dopamine receptor subtypes and incentive learning explains that dopamine receptors are G protein-coupled and form two families: D1-like receptors, including D1 and D5, stimulate adenylyl cyclase and cyclic adenosine monophosphate (cAMP); D2-like receptors, including D2, D3, and D4, inhibit cAMP. Antipsychotic medications are dopamine receptor antagonists and their clinical potency is strongly correlated with blockade of D2 receptors, implicating overactivity of D2 receptors in psychosis in schizophrenia. D1- and D2-like receptors appear to be involved in unconditioned locomotor activity and incentive learning. D1-like receptors are implicated more strongly in incentive learning and D2-like receptors more strongly in locomotion. D3 receptors may play a relatively greater role in expression than acquisition of incentive learning. Dopamine receptor subtypes form heteromers with each other and with the receptors of other neurotransmitters (e.g., glutamate, adenosine, ghrelin) and the signaling properties of these heteromers can differ from those of either receptor in isolation.

APA, Harvard, Vancouver, ISO und andere Zitierweisen

44

Lee, Samuel Paikwon. Oligomerization of the D2 dopamine receptor. 2004.

Den vollen Inhalt der Quelle finden

APA, Harvard, Vancouver, ISO und andere Zitierweisen

45

Waddington, John L. D1: D2 Dopamine Receptor Interactions (Neuroscience Perspectives). Academic Press, 1993.

Den vollen Inhalt der Quelle finden

APA, Harvard, Vancouver, ISO und andere Zitierweisen

46

Waddington, John L. D1: D2 Dopamine Receptor Interactions (Neuroscience Perspectives). Academic Press, 1993.

Den vollen Inhalt der Quelle finden

APA, Harvard, Vancouver, ISO und andere Zitierweisen

47

Creese, Ian, und Claire M. Fraser. Dopamine Receptors (Receptor Biochemistry and Methodology, Vol 8). John Wiley & Sons, 1987.

Den vollen Inhalt der Quelle finden

APA, Harvard, Vancouver, ISO und andere Zitierweisen

48

Oldenhof, John. SH3 binding domains in the dopamine D4 receptor. 1999.

Den vollen Inhalt der Quelle finden

APA, Harvard, Vancouver, ISO und andere Zitierweisen

49

Borgundvaag, Bjug. Dopamine receptor mediated inhibition of anterior pituitary adenylate cyclose. 1985.

Den vollen Inhalt der Quelle finden

APA, Harvard, Vancouver, ISO und andere Zitierweisen

50

Clozapine congeners: Structural requirements for dopamine D4 receptor selectivity. Ottawa: National Library of Canada = Bibliothèque nationale du Canada, 1995.

Den vollen Inhalt der Quelle finden

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Wir bieten Rabatte auf alle Premium-Pläne für Autoren, deren Werke in thematische Literatursammlungen aufgenommen wurden. Kontaktieren Sie uns, um einen einzigartigen Promo-Code zu erhalten!